Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

AUSTIN, Texas, April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new ...

Related Keywords

Texas ,United States ,Aeglea Biotherapeutics ,Deric Bradford ,Anthonyg Quinn ,Society For Inherited Metabolic Disorders ,Drug Administration ,Prnewswire Aeglea Biotherapeutics Inc ,Nasdaq ,Exchange Commission ,European Medicines Agency ,Aeglea Biotherapeutics Inc ,Laboratory Measure ,Inherited Metabolic Disorders ,Annual Meeting ,Patient Level Outcomes ,Gross Motor Function Classification System ,Score Range ,Additional Secondary Efficacy Endpoints ,Baseline Relative ,About Pegzilarginase ,Rare Pediatric Disease ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Orphan Drug Designation ,European Medicines ,Forward Looking ,Securities Litigation Reform Act ,Annual Report ,